Royal Philips has launched a new 12-lead electrocardiogram (ECG) solution designed to be used at home by patients participating in clinical trials.
According to the company, this is the first ECG offering of its kind. The device securely transmits patient data, limiting the need for on-site visits and increasing the likelihood that a trial will reach its conclusion. No onsite technicians or nurses need to be present for patients to record their data.
“Our customers are seeking solutions that will help them to address key challenges that can stand in the way of extracting meaningful insights from their clinical trials,” Andy Broadway, general manager of ambulatory monitoring and diagnostics at Philips, said in a prepared statement. “Our growing portfolio of remote monitoring solutions help to curb patient attrition by reducing the amount of site visits required during the trial period, helping to improve both the quality of the outcome and the patient experience overall.”
The at-home solution is now available in “select markets” throughout North America, Europe and Asia.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.